Clinical Trial Update: An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects. [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 open-label trial of TMC114/RTV (darunavir/ritonavir) in HIV-1 infected, treatment-experienced subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Darunavir (darunavir)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infection | Phase 2 | Status: COMPLETED